News
LBTSF
15.35
NaN%
--
Eli Lilly wins FDA nod for eight-week dosing regimen of eczema therapy Ebglyss
Seeking Alpha · 11h ago
Almirall Boosts Capital as Most Shareholders Choose Stock Over Cash in Flexible Dividend
TipRanks · 5d ago
Almirall Expands Capital as Majority of Shareholders Opt for Scrip Dividend
TipRanks · 6d ago
Almirall Schedules Webcast to Present Q1 2026 Results to Investors
TipRanks · 05/12 13:59
Almirall Shareholders Approve 2025 Accounts, Dividend and Financing Flexibility
TipRanks · 05/12 13:59
Almirall Opts for Scrip Dividend via Capital Increase from Reserves
TipRanks · 05/12 13:58
Almirall Refines Board Committees and Advances Scrip Dividend Plan
TipRanks · 05/12 13:57
Almirall Issues Cautious Q1 2026 Financial and Business Update
TipRanks · 05/12 13:57
Almirall Sets Timetable for 2026 Scrip Dividend and Bonus Share Issue
TipRanks · 05/12 13:56
Almirall Corrects Reference Share Price for Scrip Dividend Capital Increase
TipRanks · 05/12 13:52
Almirall, S.A. reports Q1 results
Seeking Alpha · 05/11 18:53
Almirall Calls 2026 Shareholders’ Meeting with Governance Changes and Scrip Dividend Plan
TipRanks · 04/08 17:37
Lilly says once-monthly eczema injectable delivered durable disease control
Seeking Alpha · 03/27 15:02
Almirall presents long-term interim results from Phase 3b ADlong study
TipRanks · 03/27 13:05
Almirall presents clinical, real-word data across portfolio at AAD meeting
TipRanks · 03/26 11:15
Almirall Updates Board Regulations to Strengthen Corporate Governance Framework
TipRanks · 03/19 14:24
Almirall downgraded to Hold from Buy at Deutsche Bank
TipRanks · 03/02 10:30
Kepler Capital Sticks to Their Buy Rating for Almirall (0O9B)
TipRanks · 02/25 01:38
Almirall Schedules Webcast to Present 2025 Financial Results
TipRanks · 02/24 12:04
Almirall Publishes 2025 Corporate Governance Report in Enhanced Narrative Format
TipRanks · 02/24 12:04
More
Webull provides a variety of real-time LBTSF stock news. You can receive the latest news about Almirall through multiple platforms. This information may help you make smarter investment decisions.
About LBTSF
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.